GlassScriptPhysician profile
Kaitklin Stoldt
NPI 1891192829
$821.43
in general payments reported to CMS, 2019-2025
8 companies · $436 in 2025
The $436 reported for 2025 was more than what 77% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.34 · 2022: $24.06 · 2023: $67.28 · 2024: $196 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avita Medical Americas, LLC | $447.57 | 2024-2025 | Recell, Cohealyx, Permeaderm |
| Abbvie INC. | $135.76 | 2025 | |
| Innocoll Pharmaceuticals Limited | $58.32 | 2021-2022 | |
| Organogenesis INC. | $48.42 | 2024 | |
| Integra Lifesciences Corporation | $45.76 | 2021 | |
| Smith+Nephew, INC. | $35.14 | 2021-2023 | Collagenase Santyl |
| Kerecis Limited | $30.42 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Kci USA, INC. | $20.04 | 2023 | Prevena Restor Bellaform |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitklin Stoldt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.